Evidence map›Paper›PMID 25445719›Full record

ReviewAdvanced drug delivery reviews2015

Spatial regulation of controlled bioactive factor delivery for bone tissue engineering.

Julia E Samorezov, Eben Alsberg

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Up-to-date progress in bioprinting of bone tissue.International journal of bioprinting · 2023
    Review
  16. Engineering Spatiotemporal Control in Vascularized Tissues.Bioengineering (Basel, Switzerland) · 2022
    Review
  17. Statistic Copolymers Working as Growth Factor-Binding Mimics of Fibronectin.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Article
  18. Review
  19. Review
  20. Dual drug delivery platforms for bone tissue engineering.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Julia E SamorezovDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Eben AlsbergDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA; Department of Orthopaedic Surgery, Case Western Reserve University, Cleveland, OH, USA; National Center for Regenerative Medicine, Division of General Medical Sciences, Case Western Reserve University, Cleveland, OH, USA. Electronic address: eben.alsberg@case.edu.

Funding

The Epidemiology of Human Chondrogenic Progenitor CellsR01AR063733 · NIAMS · CLEVELAND CLINIC LERNER COM-CWRU · PI MUSCHLER, GEORGE F · 2013 to 2016
$2.5M
Driving Tissue Formation by Inductive Stem Cell Sheet TechnologyR01AR063194 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN · 2012 to 2016
$1.7M
Growth Plate RegenerationR21AR061265 · NIAMS · CLEVELAND CLINIC LERNER COM-CWRU · PI ALSBERG, EBEN, BALLOCK, ROBERT TRACY · 2012 to 2013
$392k
Controlled, Sustained Delivery of siRNA to hMSCs for Enhanced Bone RegenerationR56DE022376 · NIDCR · CASE WESTERN RESERVE UNIVERSITY · PI ALSBERG, EBEN · 2012 to 2012
$346k
NIAMS NIH HHS R01AR053733NIAMS NIH HHS R01 AR063194NIAMS NIH HHS R01AR063194NIAMS NIH HHS R01 AR063733NIAMS NIH HHS R21 AR061265NIAMS NIH HHS R21AR061265NIDCR NIH HHS R56 DE022376NIDCR NIH HHS R56DE022376
6 · The paper itself

Abstract

Limitations of current treatment options for critical size bone defects create a significant clinical need for tissue engineered bone strategies. This review describes how control over the spatiotemporal delivery of growth factors, nucleic acids, and drugs and small molecules may aid in recapitulating signals present in bone development and healing, regenerating interfaces of bone with other connective tissues, and enhancing vascularization of tissue engineered bone. State-of-the-art technologies used to create spatially controlled patterns of bioactive factors on the surfaces of materials, to build up 3D materials with patterns of signal presentation within their bulk, and to pattern bioactive factor delivery after scaffold fabrication are presented, highlighting their applications in bone tissue engineering. As these techniques improve in areas such as spatial resolution and speed of patterning, they will continue to grow in value as model systems for understanding cell responses to spatially regulated bioactive factor signal presentation in vitro, and as strategies to investigate the capacity of the defined spatial arrangement of these signals to drive bone regeneration in vivo.

Indexed as

Biocompatible MaterialsBone and BonesDrug Delivery SystemsHumansIntercellular Signaling Peptides and ProteinsTissue EngineeringBiocompatible MaterialsIntercellular Signaling Peptides and ProteinsBiomaterials patterningBone regenerationDrug deliverySpatial regulationTemporal regulation

Identifiers

PMID25445719
PMCPMC4428953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.